The Impact of Accelerometer Use in Exercise-Associated Hypoglycemia Prevention in Type 1 Diabetes

Size: px
Start display at page:

Download "The Impact of Accelerometer Use in Exercise-Associated Hypoglycemia Prevention in Type 1 Diabetes"

Transcription

1 551045DSTXXX / Journal of Diabetes Science and TechnologyStenerson et al research-article2014 Original Article The Impact of Accelerometer Use in Exercise-Associated Hypoglycemia Prevention in Type 1 Diabetes Journal of Diabetes Science and Technology 2015, Vol. 9(1) Diabetes Technology Society Reprints and permissions: sagepub.com/journalspermissions.nav DOI: / dst.sagepub.com Matthew Stenerson, MD 1, Fraser Cameron, PhD 2, Shelby R. Payne, BS 1, Sydney L. Payne, BS 1, Trang T. Ly, MBBS, FRACP, PhD 1, Darrell M. Wilson, MD 1, and Bruce A. Buckingham, MD 1 Abstract Background: Exercise-associated hypoglycemia is a common adverse event in people with type 1 diabetes. Previous in silico testing by our group demonstrated superior exercise-associated hypoglycemia mitigation when a predictive low glucose suspend (PLGS) algorithm was augmented to incorporate activity data. The current study investigates the effectiveness of an accelerometer-augmented PLGS algorithm in an outpatient exercise protocol. Methods: Subjects with type 1 diabetes on insulin pump therapy participated in two structured soccer sessions, one utilizing the algorithm and the other using the subject s regular basal insulin rate. Each subject wore their own insulin pump and a Dexcom G4 Platinum continuous glucose monitor (CGM); subjects on-algorithm also wore a Zephyr BioHarness 3 accelerometer. The algorithm utilized a Kalman filter with a 30-minute prediction horizon. Activity and CGM readings were manually entered into a spreadsheet and at five-minute intervals, the algorithm indicated whether the basal insulin infusion should be on or suspended; any changes were then implemented by study staff. The rate of hypoglycemia during and after exercise (until the following morning) was compared between groups. Results: Eighteen subjects (mean age 13.4 ± 3.7 years) participated in two separate sessions 7-22 days apart. The difference in meter blood glucose levels between groups at each rest period did not achieve statistical significance at any time point. Hypoglycemia during the session was recorded in three on-algorithm subjects, compared to six off-algorithm subjects. In the postexercise monitoring period, hypoglycemia occurred in two subjects who were on-algorithm during the session and four subjects who were off-algorithm. Conclusions: The accelerometer-augmented algorithm failed to prevent exercise-associated hypoglycemia compared to subjects on their usual basal rates. A larger sample size may have achieved statistical significance. Further research involving an automated system, a larger sample size, and an algorithm design that favors longer periods of pump suspension is necessary. Keywords accelerometer, exercise, hypoglycemia, predictive low glucose suspend, pump suspension, type 1 diabetes Hypoglycemia is a common and potentially dangerous side effect of exercise in people with type 1 diabetes (T1D). 1-3 Although suspension of insulin delivery at the beginning of moderate aerobic exercise reduces the risk of exercise-associated hypoglycemia, the risk of hyperglycemia is increased. 4 Glucose threshold-based insulin pump suspension has been shown to reduce the duration of exercise-induced hypoglycemia and can be performed in a user-independent manner. 5 Our group previously augmented our predictive low glucose suspend (PLGS) algorithm to incorporate physical activity using a combined accelerometer/heart rate monitor. 6 The activity-informed algorithm showed superior hypoglycemia mitigation compared to the PLGS algorithm alone using in silico testing. 7 The current study investigates the effectiveness of an accelerometer-augmented PLGS algorithm in the real-life setting of an outpatient exercise protocol. We hypothesized that 1 Division of Pediatric Endocrinology, Stanford University, Stanford, CA, USA 2 Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, USA Corresponding Author: Bruce A. Buckingham, MD, Division of Pediatric Endocrinology, Stanford University, 300 Pasteur Dr, Rm G-313, Stanford, CA , USA. buckingham@stanford.edu

2 Stenerson et al 81 the accelerometer-augmented algorithm would significantly reduce the incidence of exercise-associated hypoglycemia compared to subjects usual basal rates, without an increase in hyperglycemia. Methods Study Design This was a pilot study employing a randomized crossover design. Subjects with type 1 diabetes participated in a structured soccer session on two separate dates at least one week apart. During one session a subject s basal insulin rate was continued ( off-algorithm ), while during the other session the algorithm (see algorithm monitoring below) was in effect ( on-algorithm ); the order of on- versus off-algorithm was chosen at random. The rate of hypoglycemia and change in blood glucose during exercise were compared between each group. Hypoglycemia was defined as (1) any meter blood glucose (BG) reading of 60 mg/dl, (2) two consecutive meter BG readings 70 mg/dl done within one hour, or (3) any instance in which carbohydrates were given at a subject s request for symptoms of hypoglycemia (regardless of corresponding meter BG reading). Eligibility Criteria and Assessment Subject recruitment took place at Stanford University. To be eligible for the study, each subject had to (1) be between 8 and 25 years of age, (2) have a clinical diagnosis of type 1 diabetes for 1-20 years, (3) use a downloadable insulin pump (with programmable carbohydrate to insulin ratios, correction doses, and insulin on board features) for insulin delivery, (4) own a continuous glucose monitor (CGM) or agree to wear a loaned CGM for purposes of study participation, and (5) have a hemoglobin A1c < 10%. Subjects were not eligible if they had an episode of severe hypoglycemia resulting in seizure or loss of consciousness in the prior four weeks. Clinic Visit Procedures At 1-3 days prior to the first soccer session, subjects had an initial visit with a study investigator for a baseline medical history and physical exam. A hemoglobin A1c was obtained using the Bayer DCA 2000 (Bayer HealthCare LLC, Mishawaka, IN). For those subjects not already using one, a Dexcom G4 Platinum CGM (Dexcom Inc, San Diego, CA) was placed on the abdomen, arm, or buttocks. Each subject also received a Bayer Contour Next EZ glucometer (Bayer HealthCare LLC, Mishawaka, IN) for calibration of the CGM. Pre-exercise Procedures Subjects were instructed to calibrate the CGM using their studyissued glucometer twice daily and on the morning of soccer. For breakfast on the morning of the soccer session, subjects bolused via their insulin pumps for all but g of carbohydrates, with the goal of avoiding hypoglycemia prior to the start of the session. This also mimics the common practice of subjects to not provide insulin coverage for g of carbohydrates in a meal prior to exercise ( exercise carbohydrates ). Subjects were instructed to consume the same meal before each session. Subjects arrived at the soccer field minutes prior to the session s start time. Upon arrival, initial meter BG and CGM glucose values were recorded. The CGM was recalibrated if there was a >20% difference between the glucometer reading and CGM value, unless the CGM demonstrated a rapid rate of change ( 2 mg/dl/min) in either direction. For meter BG < 120 mg/dl, subjects were given g carbohydrates and held back from starting exercise until meter BG measured > 120 mg/dl. For meter BG > 300 mg/dl, serum ketones were assessed using the Precision Xtra blood ketone meter (Abbott Laboratories, Abbott Park, IL). Infusion sets were changed if serum ketones were >0.3 mmol/l. For those subjects who were on-algorithm, the Zephyr BioHarness 3 (Zephyr Technology, Annapolis, MD) accelerometer was secured around the waist via a nylon strap. Activity data that were measured by the accelerometer were beamed via Bluetooth to an Android cell phone using the SenseView app (Mobili d.o.o., Ljubljana, Slovenia), resulting in a real-time Activity output graph that was followed using the phone s screen by an assigned study staff member. Intraexercise Procedures Subjects performed a final meter BG check just prior to the start of exercise. For those with BGs > 120 mg/dl, soccer practice began at 10:00 am. Each session involved skill-building activities across various ranges of exercise intensity (Table 1). Subjects had four segments of activity lasting approximately minutes each, with three rest periods of five minutes duration in between each Activity interval, during which subjects checked their meter BG. The CGM was recalibrated if there was a >20% difference between the glucometer reading and CGM value, unless the CGM demonstrated a rapid rate of change ( 2 mg/dl/min) in either direction. Unless hypoglycemic, subjects consumed only water throughout the duration of the session. However, in the event of hypoglycemia, subjects were given g of carbohydrates and their insulin pump was suspended for 30 minutes. Subjects were also removed from play and were not allowed to return until meter BG was >120 mg/dl. Additional carbohydrates beyond the g were given if there was not a substantial rise in the meter BG after 15 minutes. Algorithm Monitoring The pump suspension algorithm follows three rules based on a 30-minute prediction from a Kalman filter and the Activity readings from the accelerometer. First, insulin delivery is resumed if the CGM readings are rising. This rule trumps all other rules. Second, the pump is suspended if the 30-minute

3 82 Journal of Diabetes Science and Technology 9(1) Table 1. Typical Exercise Session, Which Included Skill-Building Activities of Various Intensity Levels and Three Rest Periods for Water and BG Checks. Activity Time (min) Intensity (1-10) Dynamic warm-up 10 5 Dribbling in a cone grid 10 6 Dribbling relays and figure 8s 5 4 rest 5 1 Speed ladder, cone slalom 15 7 Dribbling, shooting on goal 10 6 rest 5 1 Passing and moving 10 6 Shuttle run 5 10 Mini scrimmage 15 9 rest 5 1 Full scrimmage 25 9 Intensity levels are based on an independent scale in which 1 is equivalent to very light activity, 3 is light activity, 5 is moderate activity, 7 is hard activity, and 10 is very hard activity. prediction is below 80 mg/dl. Third, the pump is suspended if the CGM is below 180 mg/dl and the Activity averaged over 80 seconds is above 0.3, measured in Zephyr s proprietary units. (The values of 80 seconds, and 0.3 represent the retro-fitted parameters that best matched actual performance. A value of 0.3 represents the activity level of very light walking.) The assigned staff member judged Activity by eye using the screen of an Android phone. The algorithm was run using Excel (Microsoft Corporation, Redmond, WA) on a research laptop computer. Each subject who was on-algorithm had one assigned study staff member to follow his or her Activity and CGM trends. In five-minute intervals, the staff member manually entered into Excel the average observed Activity value over those five minutes, as well as the CGM glucose value at the end of that interval. Based on these data points, the algorithm then generated one of two messages for pump status: pump on or pump off. Algorithm determination of pump status was then implemented by the study staff: the assigned staff member manually suspended the subject s pump when commanded to turn the pump off, or manually resumed insulin delivery when commanded to turn the pump on (Table 2). At the conclusion of the soccer session, subjects basal rates were resumed. Postexercise Procedures Immediately following the completion of the soccer session, subjects on-algorithm had their accelerometers removed and all subjects were provided lunch. Subjects were instructed to resume their usual postexercise diabetes management, with no further intervention from study staff. However, subject monitoring was continued via continued use of the CGM and study-issued meter for all BG checks until breakfast the following morning to assess for postexercise hypoglycemia. Statistical Analysis Mean and standard deviation meter BG values were tabulated using Excel. The difference in rates of hypoglycemia between the on-algorithm and off-algorithm groups was analyzed by group analysis using a 2-sided Fischer s exact test. Results A total of 18 subjects (eight female) participated in two separate soccer sessions 7-22 days apart. Mean age was 13.4 years (±3.7 years, range 9.4 to 25 years) and mean hemoglobin A1c was 8.0% (±1.1%, range 5.5% to 9.9%). Eleven subjects were using a Medtronic pump, four were using an OmniPod pump, two an Animas pump, and one a Tandem pump. Of note, on arrival to the soccer field there were four subjects with meter BG values >300 (2 involving on-algorithm participants, the other two off-algorithm); a partial insulin bolus (generally half of the insulin pump s recommended bolus) was administered prior to the start of soccer for these subjects. For each soccer session, the dosage of each subject s breakfast-time insulin and intraexercise insulin as well as nadir glucose levels during exercise are shown in Table 3. The timing of insulin suspension and carbohydrate treatment for hypoglycemia in both groups is shown in Figure 1, including the aggregate number of patients whose pumps were suspended at any given five-minute interval throughout the soccer session. There was no difference in the meter BG values at the start of soccer between the on-algorithm group and the off-algorithm group (204.7 ± 63.7 mg/dl and ± 54.5 mg/dl, respectively; P =.40). Meter BG values at the scheduled checks throughout the session are shown in Figure 2. The difference in meter BGs between groups at each rest period did not achieve statistical significance at any time point. Hypoglycemia during the soccer session was recorded

4 Stenerson et al 83 Table 2. Sample Algorithm Flow Sheet (Subject 6). Time (HH:MM) CGM glucose (mg/dl) Activity reading 30-min glucose prediction (mg/dl) Desired pump state 9: : Off 10: Off 10: Off 10: Off 10: Off 10: On 10: Off 10: Off 10: Off 10: Off 10: Off 10: Off 11: On 11: On 11: On 11: On 11: On 11: On 11: Off 11: Off 11: Off 11: Off 11: Off 11: On 12: Off CGM glucose and average activity were entered in five-minute intervals, prompting the algorithm to generate a 30-minute glucose prediction and desired pump state (on vs off). Based on the algorithm s suggestion, staff pulled a subject aside to make recommended changes in pump status. in three on-algorithm subjects, compared to six off-algorithm subjects (P =.45). In future studies we plan to have the algorithm communicating directly with the insulin pump to initiate pump suspensions. We therefore performed a post hoc analysis of the data to determine the difference in pump suspensions if they had occurred automatically compared to manually. If pumps had been suspended automatically, the amount of time the pumps would have been suspended would have been decreased by 3%. In the postexercise monitoring period (during which subjects made their own insulin adjustments and were not restricted on food consumption), hypoglycemia occurred in two subjects who were on-algorithm during the soccer session and four subjects who were off-algorithm (P =.66). The distribution of CGM glucose values throughout the postexercise monitoring period was not significantly different between the two groups. Discussion Exercise-associated hypoglycemia is a common adverse event in people with T1D, 1-3 in part because of inappropriate insulin adjustments to account for the increased insulin sensitivity associated with exercise. 8,9 Children and adolescents are at particular risk due to notoriously suboptimal adherence to their insulin regimens. 10,11 Thus, as a user-independent means of insulin management, the artificial pancreas a system of closed-loop communication between a CGM and an insulin pump under algorithmic control 12 offers a unique opportunity for hypoglycemia prevention/mitigation. However, although a control-to-range algorithm augmented with heart rate data and a low glucose suspend algorithm have shown encouraging results, the use of algorithmic controls to prevent hypoglycemia in the exercise setting is still a fledgling venture in artificial pancreas research. 5,13 To our knowledge, the current study is the first in which an accelerometer-augmented insulin pump suspension algorithm has been tested in the setting of an outpatient exercise protocol. In previous in silico testing, the activity-informed algorithm showed superior hypoglycemia mitigation compared to a PLGS algorithm alone. 7 However, in the real-life setting of the current study, there was no statistically significant difference in the on-algorithm versus off-algorithm groups with regard to average final BG, nor in the number of hypoglycemia events either during or postexercise. We suspect that the

5 84 Journal of Diabetes Science and Technology 9(1) Table 3. Dosage of Each Subject s Breakfast-Time Insulin (Cumulative Insulin Boluses Within Four Hours of Session Start Time), Intraexercise Insulin, and Nadir Glucose Levels at Each Soccer Session. Breakfast insulin Exercise insulin Nadir glucose (meter/sensor) Subject ID On-algorithm Off-algorithm On-algorithm Off-algorithm On-algorithm Off-algorithm /56 49/ /NA 83/ / / /56 57/ / / /76 77/ /139 66/ / / / / /105 67/ /NA 161/ /148 66/ /83 59/ /131 80/ a a /97 a 53/ /129 87/ /95 189/ / /164 a On-algorithm data counted as off-algorithm because pump erroneously stayed on despite attempts to suspend. NA, not able to be determined due to extended periods of sensor failure during exercise. Figure 1. Overview of insulin delivery status for all subjects whose pumps were suspended at least once during the soccer session. The bar graph in the top pane details the percentage of pumps suspended at any given time in five-minute intervals. Lines in the bottom pane demonstrate each subject s pump status throughout the two-hour session (black = off-algorithm, blue = on-algorithm). For subjects in the off-algorithm group, pumps were suspended only if meter BG (not shown) was 60 mg/dl or the subject request treatment for hypoglycemia. Carbohydrate interventions for hypoglycemia are depicted as squares. lack of superior hypoglycemia prevention in this real-life setting may in part be due to a small sample size and an insufficient number of hypoglycemic events in the off-algorithm group. The latter was partly the result of our use of free or exercise carbohydrates that subjects were instructed to consume prior to the soccer session (10-30 g); this resulted in an average starting BG >180 mg/dl, so that the incidence of hypoglycemia in the control arm was 33%, compared to an expected incidence of about 43%. 4 We also suspect that the lack of superior hypoglycemia prevention may in part be due to the algorithm s over-aggressiveness in favoring the pump on status even with BGs bordering hypoglycemia, as seen with Subject 6 in Table 2. Future adjustments to the algorithm may include a threshold above zero on the glucose rate of change for resumption of insulin delivery when activity has occurred in the recent past and glucose levels are less than 80 or 90 mg/dl. These changes would favor more pump suspension, decreasing the risk of hypoglycemia both during and after exercise. Although adjustments are needed, the resumption of insulin delivery using the current algorithm did not result in any difference in hyperglycemia between the on-algorithm and off-algorithm groups. This highlights the benefits of algorithmic control over the arbitrary suspension of insulin delivery at the beginning of exercise; in a study carried out by the DirecNet group, such arbitrary suspension demonstrated hypoglycemia prevention in 57% of subjects, but hyperglycemia in 27% of subjects (compared to 4% of controls) shortly after the completion of exercise. 4 An additional limitation of the study is related to the potential for operator error in regard to both triggering the

6 Stenerson et al 85 Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Lilly Endocrine Scholars Award; the Ernest and Amelia Gallo Endowed Postdoctoral Fellowship; the Child Health Research Institute; and the Stanford Clinical & Translational Science Award, grant UL1 RR Figure 2. Mean meter BG values from the start of the exercise session to the end. For subjects who met hypoglycemia criteria prior to a rest period, the meter BG for those subjects is reflected in the immediately subsequent rest period; any meter BGs thereafter were removed, resulting in a progressively lower N. algorithm and carrying out the algorithms commands. Using the SenseView app, staff members observed Activity readings in 5-minute segments and entered into Excel an observed average Activity number over that time. As an estimate, this number was less reliable than an automated system. In addition, with staff members being responsible for manually suspending and resuming delivery on a subject s pump, delays in pump suspension and resumptions of delivery also occurred, which could have been avoided using an automated system. Conclusions In this pilot study investigating the effectiveness of an accelerometer-augmented pump suspension at hypoglycemia prevention in an outpatient exercise protocol, the algorithm did not prevent exercise-associated hypoglycemia. This lack of statistical significance may in part have been related to an overaggressive bias toward insulin delivery. However, small sample size and the requirement for manual interpretation of data and carrying out of algorithm commands may also have played a role. We therefore remain optimistic about the potential for accelerometer-augmented algorithms to provide a meaningful contribution in an artificial pancreas. Further research involving an automated system, a larger sample size, and an algorithm design that favors longer periods of pump suspension is necessary. Abbreviations BG, blood glucose; CGM, continuous glucose monitor; PLGS, predictive low glucose suspend; T1D, type 1 diabetes. References 1. Tansey MJ, Tsalikian E, Beck RW, et al. The effects of aerobic exercise on glucose and counterregulatory hormone concen-trations in children with type 1 diabetes. Diabetes Care. 2006;29: MacDonald MJ. Postexercise late-onset hypoglycemia in insulindependent diabetic patients. Diabetes Care. 1987;10: Shehadeh N, Kassem J, Tchaban I, et al. High incidence of hypoglycemic episodes with neurologic manifestations in children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab. 1998;11(suppl 1): Tsalikian E, Kollman C, Tamborlane WB, et al. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care. 2006;29: Garg S, Brazg RL, Bailey TS, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther. 2012;14: Cameron F, Wilson DM, Buckingham BA, et al. Inpatient studies of a Kalman-filter-based predictive pump shutoff algorithm. J Diabetes Sci Technol. 2012;6: Stenerson M, Cameron F, Wilson DM, et al. The impact of accelerometer and heart rate data on hypoglycemia mitigation in type 1 diabetes. J Diabetes Sci Technol. 2014;8: Devadoss M, Kennedy L, Herbold N. Endurance athletes and type 1 diabetes. Diabetes Educ. 2011;37: Bernardini AL, Vanelli M, Chiari G, et al. Adherence to physical activity in young people with type 1 diabetes. Acta Biomed. 2004;75: Burdick J, Chase HP, Slover RH, et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics. 2004;113:e221-e O Connell MA, Donath S, Cameron FJ. Poor adherence to integral daily tasks limits the efficacy of CSII in youth. Pediatr Diabetes. 2011;12: Peyser T, Dassau E, Breton M, Skyler JS. The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci. 2014;1311: Breton MD, Brown SA, Karvetski CH, et al. Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes. Diabetes Technol Ther. 2014;16:1-6.

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,

More information

Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension

Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension DIABETES TECHNOLOGY & THERAPEUTICS Volume 11, Number 2, 29 Mary Ann Liebert, Inc. DOI: 1.189/dia.28.32 Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension Bruce Buckingham,

More information

Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm

Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm Journal of Diabetes Science and Technology Volume 6, Issue 5, September 2012 Diabetes Technology Society ORIGINAL ARTICLE Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm Fraser,

More information

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly

More information

Artificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump

Artificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.

More information

Artificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes

Artificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes Protocol Artificial Pancreas Device Systems Medical Benefit Effective Date: 07/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18, 05/18, 01/19 Preauthorization

More information

Diabetes Management: Current High Tech Innovations

Diabetes Management: Current High Tech Innovations Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:

More information

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures

More information

The In-Clinic Close Loop Experience in the US

The In-Clinic Close Loop Experience in the US The In-Clinic Close Loop Experience in the US Keystone Symposium, Practical Ways to Achieve Targets in Diabetes Care July 14, 2012 Francine Ratner Kaufman, MD Chief Medical Officer, VP Global Medical,

More information

Sensor-augmented pump systems provide insulin delivery

Sensor-augmented pump systems provide insulin delivery DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 10, 2016 Mary Ann Liebert, Inc. DOI: 10.1089/dia.2016.0216 ORIGINAL ARTICLE Effectiveness of Automated Insulin Management Features of the MiniMed c

More information

Diabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018

Diabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors

More information

CGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117

CGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117 CGM: Continuous Glucose Monitoring Making Sense of It All Objectives Review how to do a time effective interpretation of CGM and insulin pump download data Review how medications, lifestyle, and current

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bergenstal RM, Klonoff DC, Garg SK, et al. -based insulin-pump

More information

Agreement between Glucose Trends Derived from Three Simultaneously Worn Continuous Glucose Sensors

Agreement between Glucose Trends Derived from Three Simultaneously Worn Continuous Glucose Sensors Journal of Diabetes Science and Technology Volume 2, Issue 5, September 2008 Diabetes Technology Society ORIGINAL ARTICLES Agreement between Glucose Trends Derived from Three Simultaneously Worn Continuous

More information

The Realities of Technology in Type 1 Diabetes

The Realities of Technology in Type 1 Diabetes The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments

More information

Subject Index. Breastfeeding, self-monitoring of blood glucose 56

Subject Index. Breastfeeding, self-monitoring of blood glucose 56 Subject Index Animas Vibe 86, 130 Artificial pancreas clinical studies inpatient studies 175 180 outpatient studies outcome assessment 182, 183 technology 180, 181 telemedicine 182 components glucose sensor

More information

Insulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education

Insulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history

More information

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts

More information

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing

More information

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used

More information

Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home

Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home Richard M. Bergenstal 1, David C. Klonoff 2, Bruce W. Bode 3, Satish

More information

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies 1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for

More information

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm The Harvard community

More information

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest

More information

Artificial Pancreas Device System (APDS)

Artificial Pancreas Device System (APDS) Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER

More information

Advances Towards the Bionic Pancreas.

Advances Towards the Bionic Pancreas. Advances Towards the Bionic Pancreas. Ron Brazg MD, FACE Rainier Clinical Research Center Renton, WA DISCLOSURES Rainier Clinical Research Center is an independent research facility not directly affiliated

More information

Report Reference Guide

Report Reference Guide Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient

More information

Hybrid Closed Loop Status & Practical Challenges in Implementation

Hybrid Closed Loop Status & Practical Challenges in Implementation Hybrid Closed Loop Status & Practical Challenges in Implementation Bruce Buckingham, MD Buckingham@Stanford.edu Professor of Pediatric Endocrinology Stanford School of Medicine Conflict of Interests Company

More information

Future Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

Future Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida Future Direction of Artificial Pancreas Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer,

More information

Dexcom Current and Future Technology Innovations. Jorge Valdes Chief Technical Officer

Dexcom Current and Future Technology Innovations. Jorge Valdes Chief Technical Officer Dexcom Current and Future Technology Innovations 2015 Jorge Valdes Chief Technical Officer G5 App Sensor (Same as G4) Indicated for adults and children down to Age 2 years Tiny insertion needle (26Ga)

More information

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies 1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated

More information

Artificial Pancreas Device Systems

Artificial Pancreas Device Systems Artificial Pancreas Device Systems Policy Number: 1.01.30 Last Review: 1/2019 Origination: 1/2017 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for

More information

Ambulatory Artificial Pancreas Platform (AAPP) User Manual

Ambulatory Artificial Pancreas Platform (AAPP) User Manual Ambulatory Artificial Pancreas Platform (AAPP) User Manual Welcome to the Artificial Pancreas User Manual. This manual is intended to teach you how to use the system in your clinical trial. If questions

More information

Medical Policy. MP Artificial Pancreas Device Systems

Medical Policy. MP Artificial Pancreas Device Systems Medical Policy MP 1.01.30 BCBSA Ref. Policy: 1.01.30 Last Review: 01/30/2018 Effective Date: 04/01/2018 Section: Durable Medical Equipment Related Policies 1.01.20 Continuous or Intermittent Monitoring

More information

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.

More information

1 Dexcom G4 Platinum User Guide May 2012

1 Dexcom G4 Platinum User Guide May 2012 1 Dexcom G4 Platinum User Guide May 2012 Page 1. Dexcom G4 PLATINUM Continuous Glucose Monitoring System. CE marked for use in 1Dexcom G4 User Guide, May 2012. LBL-011277 Rev04. color display. Dexcom G4

More information

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at

More information

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT Min-Jye Chen, MD Endocrinology Diabetes Management of the School-Aged Child Provided by Texas Children s Hospital Provider #18-267764-A

More information

Diabetes through my eyes. Rick Mauseth, M.D. W.A.D.E. April 2013

Diabetes through my eyes. Rick Mauseth, M.D. W.A.D.E. April 2013 Diabetes through my eyes Rick Mauseth, M.D. W.A.D.E. April 2013 Ant hills Total Available Glucose utilized Two drops of urine in test tube Add 10 drops of water Added tablet Foamed and got hot Compared

More information

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK) Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection

More information

Technology for Diabetes: 101 Basic Rules of the Road. Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE

Technology for Diabetes: 101 Basic Rules of the Road. Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE Technology for Diabetes: 101 Basic Rules of the Road Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE Quick Pump Facts! o Constant insulin supply o Pager-sized mini-computer worn

More information

When Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

When Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center

More information

Presented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD

Presented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce

More information

Continuous Glucose Monitoring (CGM)

Continuous Glucose Monitoring (CGM) Continuous Glucose Monitoring (CGM) Date of Origin: 02/2001 Last Review Date: 07/26/2017 Effective Date: 07/26/2017 Dates Reviewed: 04/2004, 04/2005, 03/2006, 11/2006, 12/2007, 03/2008, 09/2008, 04/2009,

More information

Interpretation of Continuous Glucose Monitoring (CGM) Data

Interpretation of Continuous Glucose Monitoring (CGM) Data Interpretation of Continuous Glucose Monitoring (CGM) Data Sherri Horvat, BSN, RN, CDE Blood Glucose Manager, Animas Corporation A Johnson & Johnson Diabetes Care Company Overview of CGM Continuous glucose

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid

More information

Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring

Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring Emerging Treatments and Technologies O R I G I N A L A R T I C L E Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring A safety net for the artificial pancreas EYAL DASSAU, PHD

More information

WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE

WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE MAY 5, 2018 OBJECTIVES Strong understanding of diabetes and its management

More information

RELEASED. Clearing your active insulin

RELEASED. Clearing your active insulin To clear all your settings: 1. Make sure the pump is not connected to your body. 2. Go to the Manage Settings screen. Menu > Utilities > Manage Settings 3. Simultaneously press and hold and until the Manage

More information

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal

More information

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA

More information

James J. Chamberlain, MD 1, Dana Dopita, RN, MSN, CDE 1, Emily Gilgen, RD, CD, CDE 1, and Annie Neuman, MPA, PA-C 1.

James J. Chamberlain, MD 1, Dana Dopita, RN, MSN, CDE 1, Emily Gilgen, RD, CD, CDE 1, and Annie Neuman, MPA, PA-C 1. 604633DSTXXX10.1177/1932296815604633Journal of Diabetes Science and TechnologyChamberlain et al research-article2015 Original Article Impact of Frequent and Persistent Use of Continuous Glucose Monitoring

More information

Display of Glucose Distributions by Date, Time of Day, and Day of Week: New and Improved Methods

Display of Glucose Distributions by Date, Time of Day, and Day of Week: New and Improved Methods Journal of Diabetes Science and Technology Volume 3, Issue 6, November 2009 Diabetes Technology Society ORIGINAL ARTICLES Display of Glucose Distributions by Date, Time of Day, and Day of Week: New and

More information

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing

More information

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

THERAPY MANAGEMENT SOFTWARE FOR DIABETES THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2009 Medtronic MiniMed. All rights reserved. 6025274-012_a CareLink Pro Report Reference Guide 0 p.2 Adherence

More information

POPULATION TRACKER - DREAMED USER GUIDE

POPULATION TRACKER - DREAMED USER GUIDE POPULATION TRACKER - DREAMED USER GUIDE November 2018 IFU-0011 05 TABLE OF CONTENTS TABLE OF CONTENTS GENERAL INFORMATION... 1 Product Description... 1 Glooko Intended Use... 1 DreaMed Intended Use...

More information

WOULD YOU LIKE TO REDUCE THE FEAR OF HYPOGLYCAEMIA FOR YOUR PATIENTS?

WOULD YOU LIKE TO REDUCE THE FEAR OF HYPOGLYCAEMIA FOR YOUR PATIENTS? WOULD YOU LIKE TO REDUCE THE FEAR OF HYPOGLYCAEMIA FOR YOUR PATIENTS? THE ONLY SYSTEM CLINICALLY PROVEN TO REDUCE HYPOGLYCAEMIA MINIMED 640G SYSTEM WITH SMARTGUARD TECHNOLOGY 1 HYPOGLYCAEMIA IS CHALLENGING

More information

Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD

Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction

More information

Abbott FreeStyle Libre Pro System

Abbott FreeStyle Libre Pro System , the Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:

More information

REPORT INTERPRETATION

REPORT INTERPRETATION REPORT INTERPRETATION: Interpreting ipro Professional Continuous Glucose Monitoring (CGM) Reports and Making Therapy Adjustments TARGET AUDIENCE The audience for this section is physicians, mid-level practitioners,

More information

CGM and Closing The Loop

CGM and Closing The Loop CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long

More information

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

THERAPY MANAGEMENT SOFTWARE FOR DIABETES THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2007 Medtronic MiniMed. All rights reserved. 6025274-0U2 120707 CareLink Pro Report Reference Guide 0 p.2 Sensor

More information

Emerging Automated Insulin Delivery Systems

Emerging Automated Insulin Delivery Systems Emerging Automated Insulin Delivery Systems Richard M. Bergenstal, MD International Diabetes Center Park Nicollet & HealthPartners Minneapolis, MN Presenter Name 1 Dualities: Richard M. Bergenstal, MD

More information

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 02/13/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization

More information

Next steps for success.

Next steps for success. Next steps for success. More tips for using CGM* training course. The Animas Vibe System is approved for persons age 2 and older. *Continuous Glucose Monitoring Important Safety Information The Animas

More information

Welcome to CareLink Pro

Welcome to CareLink Pro Reference Guide Welcome to CareLink Pro This guide was developed to serve as a reference for obtaining patient data and reviewing CareLink Pro reports. Getting Started with CareLink Pro Adding New Patients

More information

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles

More information

OneTouch Reveal web app Report Reference Guide

OneTouch Reveal web app Report Reference Guide OneTouch Reveal web app Report Reference Guide Your step-by-step guide to setting up and using the OneTouch Reveal web app OneTouch Verio meter OneTouch Verio Flex meter OneTouch Verio IQ meter OneTouch

More information

JDRF Perspective on Closed Loop

JDRF Perspective on Closed Loop JDRF Perspective on Closed Loop Aaron J. Kowalski, Ph.D. Assistant Vice President Treatment Therapies Juvenile Diabetes Research Foundation International 1 Presenter Disclosure Aaron Kowalski Disclosed

More information

Abbott FreeStyle Libre Pro System

Abbott FreeStyle Libre Pro System Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:

More information

Insulin Pumps and Glucose Sensors in Diabetes Management

Insulin Pumps and Glucose Sensors in Diabetes Management Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate

More information

Performance-powered. The OneTouch. Ping insulin pump and meter-remote.

Performance-powered. The OneTouch. Ping insulin pump and meter-remote. Performance-powered. The OneTouch Ping insulin pump and meter-remote. I We don t just deliver insulin. We deliver outstanding clinical performance. P36337_OTP_DetAid_OmniPodUpdate_r12.indd 1 OneTouch Ping.

More information

King s Research Portal

King s Research Portal King s Research Portal DOI: 10.1089/dia.2015.0324 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA):

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control

More information

GLOOKO DREAMED FOR ANDROID USER GUIDE

GLOOKO DREAMED FOR ANDROID USER GUIDE GLOOKO DREAMED FOR ANDROID USER GUIDE November 2018 IFU-0017 02 TABLE OF CONTENTS TABLE OF CONTENTS GENERAL INFORMATION... 2 Product Description... 2 Glooko Intended Use... 2 Dreamed Intended Use... 2

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Artificial Pancreas Device Systems Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original

More information

DIAGNOSIS OF DIABETES NOW WHAT?

DIAGNOSIS OF DIABETES NOW WHAT? DIAGNOSIS OF DIABETES NOW WHAT? DISCUSS GOALS FOR DIABETES CARE IDENTIFY COMMON COMPLIANCE- ADHERENCE ISSUES DESCRIBE TECHNOLOGY TO ASSIST AND / OR IMPROVE DIABETES CARE WHAT DO WE WANT OUR PATIENTS TO

More information

THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE

THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE Indicated for type 1 patients 14 and over. Prescription required. WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it

More information

Continuous Glucose Monitoring: Changing Diabetes Behavior in Real Time and Retrospectively

Continuous Glucose Monitoring: Changing Diabetes Behavior in Real Time and Retrospectively Journal of Diabetes Science and Technology Volume 2, Issue 3, May 2008 Diabetes Technology Society CONTROVERSIES in Continuous Glucose Monitoring Continuous Glucose Monitoring: Changing Diabetes Behavior

More information

THE ONLY SYSTEM^ CLINICALLY PROVEN TO REDUCE HYPOGLYCAEMIA

THE ONLY SYSTEM^ CLINICALLY PROVEN TO REDUCE HYPOGLYCAEMIA THE ONLY SYSTEM^ CLINICALLY PROVEN TO REDUCE HYPOGLYCAEMIA MINIMED 640G system^ with SmartGuard technology HYPOGLYCAEMIA IS CHALLENGING FOR GLYCAEMIC CONTROL 1 AND quality of life 2 Achieving good glucose

More information

WOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION

WOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION WOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION 1,2 MINIMED 640G WITH SMARTGUARD HAVE YOU CONSIDERED THE REAL IMPACT HYPOGLYCAEMIA HAS ON YOUR LIFE?

More information

INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.

INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. Waterproof to a depth

More information

USING THE MINIMED 670G SYSTEM

USING THE MINIMED 670G SYSTEM USING THE MINIMED 670G SYSTEM Instructions for the Experienced MiniMed 630G System User USING THE MINIMED 670G SYSTEM: INSTRUCTIONS FOR THE EXPERIENCED USER Checklist for starting on your MiniMed 670G

More information

What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?

What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes? What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes? Dr. Fiona Wotherspoon Consultant in Diabetes and Endocrinology Dorset County Hospital Fiona.Wotherspoon@dchft.nhs.uk

More information

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID FLUID Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent

More information

Predicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY

Predicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY Predicts and helps prevent lows with * zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY Basal-IQ Technology is not a substitute for active self-management of your diabetes. Please see back cover for

More information

Continuous Glucose Monitoring

Continuous Glucose Monitoring Continuous Glucose Monitoring What is Continuous Glucose Monitoring? Blood glucose meters measure glucose in your blood and glucose sensors measure glucose levels in the fluid around the cells They are

More information

First steps for success.

First steps for success. First steps for success. Getting to know continuous glucose monitoring (CGM). The Animas Vibe System is approved for persons age 2 and older. Important Safety Information The Animas Vibe Insulin Pump and

More information

Update on Diabetes Technology

Update on Diabetes Technology Update on Diabetes Technology Andrew Ahmann, MD Professor of Medicine Director, Harold Schnitzer Diabetes Health Center OHSU Objectives: Recognize the growing role of technology in assisting patients and

More information

UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE

UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE The insulin pump Replaces injections Delivers insulin through a soft cannula

More information

Diabetes Medical Management Plan (DMMP)

Diabetes Medical Management Plan (DMMP) Diabetes Medical Management Plan (DMMP) This plan should be completed by the student s personal diabetes health care team, including the parents/guardians. It should be reviewed with relevant school staff

More information

Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University

Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development

More information

The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes

The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,

More information

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services. Reference #: MC/L008 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)

More information

Pumping Insulin is it for your patients?

Pumping Insulin is it for your patients? Pumping Insulin is it for your patients? YOU CAN make managing diabetes easier. Fred Porcase D.O. Disclosures to Participants Conflicts Of Interest and Financial Relationships Disclosures: No professional

More information

Kathleen Dunn, RN CDE Jason Pelzek, RN CDE Ksenia Tonyushkina, MD Baystate Pediatric Endocrinology June, 2018

Kathleen Dunn, RN CDE Jason Pelzek, RN CDE Ksenia Tonyushkina, MD Baystate Pediatric Endocrinology June, 2018 Kathleen Dunn, RN CDE Jason Pelzek, RN CDE Ksenia Tonyushkina, MD Baystate Pediatric Endocrinology June, 2018 Ksenia Tonyushkina, MD 1 Objectives What does it mean to live with T1DM? Why exercise is important?

More information

Insulin Pumps - External

Insulin Pumps - External Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of

More information

USING THE MINIMED 670G SYSTEM. Instructions for the Experienced MiniMed 630G System User

USING THE MINIMED 670G SYSTEM. Instructions for the Experienced MiniMed 630G System User USING THE MINIMED 670G SYSTEM Instructions for the Experienced MiniMed 630G System User This is a supplemental guide. For complete instructions and safety information, please see your MiniMed 670G System

More information

The Artificial Pancreas

The Artificial Pancreas SAGLB.DIA.15.2.87(2). Approved October 215 The Artificial Pancreas For scientific and medical purposes only The pancreas responds to changes in blood glucose by releasing insulin (β cells) to lower blood

More information

Date of birth: Type 2 Other: Parent/guardian 1: Address: Telephone: Home: Work: Cell: address: Camper physician / health care provider:

Date of birth: Type 2 Other: Parent/guardian 1: Address: Telephone: Home: Work: Cell:  address: Camper physician / health care provider: Day & Evening Camp 2018 Specialized Health Care Diabetes Medical Management Plan Must be completed if your camper has diabetes. Parent/guardian and physician signature required. **We will also accept copies

More information